头颈癌寡转移患者单纯立体定向消融放疗或化疗联合立体定向消融放疗的GORTEC 2014-04「OMET」随机2期试验:生存且生活质量未恶化
这项多中心开放标签随机2期试验纳入69例头颈鳞癌寡转移患者,1:1分配至化疗联合SABR组(35例)或单纯SABR组(34例)。主要终点为1年总体生存且EORTC QLQ-C30整体生活质量评分未确定性恶化;可评估的59例中,单纯SABR组16/29(55.2%,90%CI 0.38-0.71)、化疗联合SABR组16/30(53.3%,90%CI 0.37-0.69)达到该终点。作者结论认为单纯SABR组生存相似、生活质量恶化更轻、毒性更少,可能是合理替代方案。
要点
- 可评估患者1年生存且生活质量未确定性恶化率:单纯SABR组55.2%(90%CI 0.38-0.71)vs 化疗联合SABR组53.3%(90%CI 0.37-0.69)。
- 生活质量恶化程度:化疗联合SABR组中位评分50.0(IQR 41.7-66.7)较单纯SABR组16.7(IQR 16.7-41.7)更深。
- 严重治疗相关毒性:化疗联合SABR组21/35(60.0%)vs 单纯SABR组3/34(8.8%,无5级毒性)。
核心结论
- 作者结论认为,在头颈鳞癌寡转移患者中省略以EXTREME方案为基础的前置化疗及西妥昔单抗维持、单用SABR,可获得相似生存,但生活质量恶化程度轻得多且毒性发生率更低。
- 作者认为单纯SABR可能是头颈鳞癌寡转移患者的合理替代方案。
研究设计与样本
- 法国头颈协作组开展的多中心开放标签随机2期GORTEC 2014-04(NCT03070366)研究。
- 入选标准为年龄≥18岁、1-3个寡转移灶、美国东部肿瘤协作组评分为0-2分。
- 2015年9月至2022年10月共69例患者按1:1随机分配至化疗联合SABR组(35例)或单纯SABR组(34例)。
- 标准治疗定义为全身治疗联合SABR(化疗联合SABR;EXTREME方案[5-氟尿嘧啶/铂类/西妥昔单抗])。
- 挽救治疗由医生自行决定。
主要发现
- 57例(82.6%)仅为肺转移,40例(58.0%)为孤立转移;基线生活质量中位评分为66.7(IQR 50.0-83.3)。
- 中位随访55.3个月(95%CI 45.0-69.7)。
- 主要终点可评估者59例中,单纯SABR组16/29(55.2%,90%CI 0.38-0.71)、化疗联合SABR组16/30(53.3%,90%CI 0.37-0.69)在1年时存活且无生活质量恶化。
- 生活质量恶化程度:化疗联合SABR组为50.0(IQR 41.7-66.7),单纯SABR组为16.7(IQR 16.7-41.7)。
- 意向治疗分析(69例)中,化疗联合SABR组中位生存42.3个月(95%CI 26.5-未达到),单纯SABR组41.1个月(95%CI 32.1-66.9);中位无进展生存分别为12.9个月(95%CI 7.5-17.3)和7.4个月(95%CI 4.2-15.6)。
关键数值与推荐
- 严重治疗相关毒性:化疗联合SABR组21/35(60.0%),单纯SABR组3/34(8.8%,无5级毒性)。
临床怎么用
- 作者认为单纯SABR可能是头颈鳞癌寡转移患者的合理替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with oligometastasis may have prolonged survival with multisite stereotactic ablative radiation therapy (SABR). Evidence to support this paradigm is scarce in squamous cell carcinoma of the head and neck (HNSCC). The multicenter open-label randomized GORTEC 2014-04 (NCT03070366) phase 2 study assesses survival without definitive quality of life (QoL) deterioration of omitting upfront chemotherapy in oligometastatic patients with HNSCC using SABR alone, in the French Head and Neck Intergroup. METHODS AND MATERIALS: Eligible participants (≥18 years old with 1-3 oligometastases, the Eastern Cooperative Oncology Group score 0-2) were randomly assigned (1:1) to receive chemo-SABR or SABR alone. Salvage treatments were left to the physician's appreciation. The standard therapy was considered to be systemic therapy and SABR (chemo-SABR; EXTREME regimen [5 fluorouracil/platinum/cetuximab]). The primary endpoint was 1-year (±3 months) overall survival rate without definitive deterioration (ie, without subsequent better QoL score) of the global European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core30 score. RESULTS: Between September 2015 and October 2022, 69 participants were assigned to receive chemo-SABR (N = 35) or SABR alone (N = 34); 57 had lung-only metastases (82.6%), and 40 had isolated metastasis (58.0%). The median baseline QoL score was 66.7 (IQR, [50.0-83.3]). The median follow-up was 55.3 months (95% CI, 45.0-69.7). Of participants (N = 59) evaluable for the primary endpoint, 16 of 29 (55.2%, 90% CI, 0.38-0.71) and 16 of 30 (53.3%, 90% CI, 0.37-0.69) were alive and free of QoL deterioration at 1 year in the SABR-alone and chemo-SABR arms. However, QoL deterioration was deeper with chemo-SABR (50.0; IQR, [41.7-66.7]) than with SABR alone (16.7; IQR, [16.7-41.7]). In intent-to-treat analysis (N = 69), median survival was 42.3 months (95% CI, 26.5-not reached) with chemo-SABR and 41.1 months (95% CI, 32.1-66.9) with SABR alone; median progression-free survival was 12.9 (95% CI, 7.5-17.3) and 7.4 months (95% CI, 4.2-15.6) in the chemo-SABR and SABR alone arms, respectively. Rates of severe treatment-related toxicities were 21 of 35 (60.0%) with chemo-SABR and 3 of 34 (8.8%, no grade 5) with SABR alone. CONCLUSIONS: Using SABR alone, the omission of upfront EXTREME-based chemotherapy and maintenance cetuximab in oligometastatic patients with HNSCC resulted in similar survival but much less severe QoL deterioration and fewer toxicity rates. SABR alone could be a reasonable alternative in oligometastatic patients with HNSCC.
引用
- Thariat J, Bosset M, Falcoz A, et al. Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR. Int J Radiat Oncol Biol Phys. 2024. PMID: 39612953. doi:10.1016/j.ijrobp.2024.11.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。